Current Pharmaceutical Design
Title: Editorial [Hot topic:Beta Cell Imaging - Why we need it and what has been Achieved (Executive Editor: Martin Gotthardt)]
Volume: 16 Issue: 14
Author(s): Martin Gotthardt
Affiliation:
Export Options
About this article
Cite this article as:
Gotthardt Martin, Editorial [Hot topic:Beta Cell Imaging - Why we need it and what has been Achieved (Executive Editor: Martin Gotthardt)], Current Pharmaceutical Design 2010; 16 (14) . https://dx.doi.org/10.2174/138161210791164135
DOI https://dx.doi.org/10.2174/138161210791164135 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
41
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medical Management and Risk Reduction of the Cardiovascular Effects of Underwater Diving
Current Vascular Pharmacology Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches
Current Vascular Pharmacology The Clinical Pathway for Hypertensive Patient of Local Health Unit, Hospitals and General Practitioners, the Milan Experience
Reviews on Recent Clinical Trials Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Preservation of Cellular Glutathione Status and Mitochondrial Membrane Potential by N-Acetylcysteine and Insulin Sensitizers Prevent Carbonyl Stress-Induced Human Brain Endothelial Cell Apoptosis
Current Neurovascular Research α-Amylase Inhibition: Some Practical Considerations
Current Enzyme Inhibition Synthesis and Investigation on the Antidiabetic Effect of 3-aryl-1-(5-methylisoxazol-3-ylamino)-1-(4-nitrophenyl) Propan-1-one
Letters in Drug Design & Discovery Editorial: Advances in Alzheimer Therapy: Something Old, Something New, Something Borrowed, Something Blue
Current Alzheimer Research The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders Activity-Based Proteomics of Lipolytic Enzymes
Current Drug Discovery Technologies Transient Elastography in HIV Infected Patients with Liver Steatosis Identifies a High-Risk Group for Non-Alcoholic Steatohepatitis
Current HIV Research The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade
Current Clinical Pharmacology Genetics and Diabetic Retinopathy
Current Diabetes Reviews Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management
Current Diabetes Reviews A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Current Pharmaceutical Design Hepatic Elimination of Drugs in Gestational Diabetes
Current Clinical Pharmacology Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?
Current Cardiology Reviews Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
Current Vascular Pharmacology Inhibition of NF-kB Activation and Cytokines Production in THP-1 Monocytes by 2-Styrylchromones
Medicinal Chemistry Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non- Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the “Low-Risk” Patients?
Current Drug Targets